ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO0352

Urinary Immature Truncated O-glycans Correlate with Glomerular and Tubulointerstitial Severity of Biopsy-Proven Diabetic Kidney Disease

Session Information

Category: Diabetic Kidney Disease

  • 702 Diabetic Kidney Disease: Clinical

Authors

  • Tanaka, Yu, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
  • Mise, Koki, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
  • Onishi, Yasuhiro, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
  • Tanabe, Katsuyuki, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
  • Uchida, Haruhito A., Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
  • Wada, Jun, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
Background

Since it has been technically challenging to quantify glycans due to their structural complexity, little is known about the association between changes of glycosylation and the progression of DKD. We previously reported that urinary levels of immature truncated O-glycans, referred to as DKD related O-glycans, strongly predicted renal prognosis in patients with type 2 diabetes (Diabetes Care. 2018;41:1765-1775). However, the association of those O-glycans in urine and blood with the pathological findings of DKD remains elusive.

Methods

We enrolled 36 patients with type 2 diabetes and biopsy-proven DKD in this study. Using serum and urine samples at renal biopsy, we measured the levels of Cy3-labeled glycoproteins binding to 45 lectins with different specificities. Specifically, we analyzed binding signals of DKD related O-glycans to the lectins, e.g. Sialyl-Tn to SNA, Galb4GlcNAc to RCA120, T-antigen to ABA, Jacalin, and ACA, and GalNAca3GalNAc to DBA. The RPS pathologic classification was used to evaluate glomerular and tubulointerstitial lesions in DKD. The relationships of glomerular classes and interstitial fibrosis and tubular atrophy (IFTA) scores with serum and urinary DKD related O-glycan levels were analyzed.

Results

At renal biopsy, 29 patients had macroalbuminuria (81%), and 7 patients showed either normoalbuminuria (11%) or microalbuminuria (8%). The profile of DKD related O-glycans in urine was distinct from that in serum. Among glomerular classes I, IIA, and IIB, urinary DKD related O-glycans gradually increased (p for trend <0.05 for all 6 glycans), while such trend was observed only in RCA120-binding O-glycans in the serum. In contrast, higher urinary levels of T-antigens recognized by ABA, Jacalin, and ACA were significantly associated with higher IFTA scores (P for trend: 0.017, 0.023, and 0.007, respectively), whereas there was no correlation between serum DKD related O-glycans and IFTA scores.

Conclusion

This study discovered that urinary levels of DKD related O-glycans, especially T-antigens, were correlated with the pathological development of early glomerular lesions and tubulointerstitial lesions. Given that such findings were observed in only urinary sample, urinary DKD related O-glycans might reflect the alteration of glycosylation in tissues of DKD.

Funding

  • Private Foundation Support

Digital Object Identifier (DOI)